Mpox Vaccine Maker Bavarian Nordic Targets Broader Access With European Submission For Imvanex Adolescent Use During WHO Emergency
Mpox Vaccine Maker Bavarian Nordic Targets Broader Access With European Submission For Imvanex Adolescent Use During WHO Emergency
生物-疫苗製造商挪迪克(Bavarian Nordic) 意在通過提交歐洲Imvanex青少年使用申請，爲更廣泛的人群提供疫苗，在世界衛生組織緊急狀態期間使用。
Bavarian Nordic A/S (OTC:BVNRY) (OTC:BVNKF) submitted clinical data on Thursday to the European Medicines Agency (EMA) to support the extension of the Imvanex (MVA-BN) smallpox and mpox vaccine indication to include adolescents 12 to 17 years of age.
挪迪克（Bavarian Nordic A/S）向歐洲藥品管理局（EMA）提交了臨床數據以支持將Imvanex（MVA-BN）天花和m痘疫苗適應症擴展至12至17歲的青少年。
Jynneos is known internationally as Imvamune or Imvanex.
Jynneos在國際上被稱爲Imvamune或Imvanex。
While currently only indicated for adults 18 years and older, the FDA granted an Emergency Use Authorization for pre- and post-exposure use in adolescents during the 2022 global pox outbreak.
雖然目前只被用於18歲及以上人群，但FDA在2022年全球痘疫爆發期間授予 adolescent 急診使用授權。
It remains the only FDA and EMA-approved pox vaccine.
它仍然是唯一獲得FDA和EMA批准的痘疫苗。
The submission is based on interim results from a clinical study sponsored by...
提交是基於由美國國家衛生研...
登入免費觀看全文
登入/註冊